Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescription is associated with reductions in risk-adjusted ...
(HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online in ...
In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).
The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...
Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
The pharmaceutical industry came up with medicine that stops people from craving processed, addictive foods and the food industry is in a panic.
The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...
With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...
Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.